HC Wainwright Downgrades Traws Pharma to Hold
HC Wainwright has revised its outlook on Traws Pharma, lowering the rating to hold, a 17.10% upside from the current price.
Key Points
- HC Wainwright downgraded Traws Pharma to a hold rating with a new price target of $1.0 on June 18, 2026.
- HC Wainwright's $1 price target implies 17.10% upside from Traws Pharma, Inc.'s ($TRAW) current $0.85 share price.
- Shares of NasdaqCM:TRAW are trading around $0.80, with a market cap of approximately $12.9 million.
- Peer funds like Dauntless Investment Group added 416,998 shares, while Squadron Capital reduced their holdings by 201,826 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has adjusted its stance on Traws Pharma, Inc. (NasdaqCM: TRAW) by downgrading the stock to a hold rating and setting a price target of $1.0. This change was announced on June 18, 2026, amid a backdrop of fluctuating share prices and market conditions.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Traws Pharma
Several institutional investors have been active in Traws Pharma. Dauntless Investment Group added 416,998 shares, bringing its total to 416,998 shares valued at approximately $763,106. Meanwhile, Squadron Capital Management trimmed its holdings by 201,826 shares, leaving it with 511,714 shares worth about $936,437. Other investors, such as Adage Capital Partners and Ikarian Capital, maintained their positions without any changes.
Traws Pharma, Inc. Stock Up 44.8%
Shares of NasdaqCM:TRAW are currently trading near $0.80. Traws Pharma has a market capitalization of about $12.9 million. The stock's 52-week range has seen a low of $0.64 and a high of $3.27. The company has a 50-day moving average of $1.43 and a 200-day moving average of $1.87. With a current ratio of 0.429 and a quick ratio of 0.365, the company faces liquidity challenges.
$TRAW price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Traws Pharma, Inc.
Insiders at Traws Pharma have been active as well. On April 16, 2026, OrbiMed Advisors LLC made multiple purchases, including one of 597,729 shares at an average price of $1.67. Earlier in the year, on March 8, 2026, Chief Financial Officer Parker Charles Nolan acquired 104,544 shares.
Analysts Set New Price Targets
On June 18, 2026, HC Wainwright & Co. downgraded Traws Pharma to a hold rating with a $1.0 price target. Previously, on May 20, 2026, the firm reiterated a buy rating with a much higher target of $8.0. As of now, the consensus recommendation is a buy, with a mean target price of $8.0 based on one analyst opinion.
About Traws Pharma
Traws Pharma, Inc., based in Newtown, Pennsylvania, is a clinical-stage biopharmaceutical company specializing in small synthetic molecules for respiratory viral diseases and cancer. The company is developing treatments for conditions like COVID-19 and influenza, including TRX01 and Tivoxavir marboxil. Traws Pharma also focuses on cancer therapies such as narazaciclib and rigosertib. Led by CEO Dr. Iain D. Dukes, the company employs four people.
Bottom Line
The downgrade by HC Wainwright reflects a more cautious outlook on Traws Pharma, which faces ongoing challenges in a competitive biotech sector. Investors keep a close watch on analyst ratings and institutional activity to gauge market sentiment. It's important to remember that these ratings are based on past performance and market conditions.
Get Traws Pharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TRAW, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.